ERBB2 and breast cancer: A recently published phase Ib study recruited patients with metastatic HER2-negative breast cancer who had progressed after at least 6 weeks of first-line treatment with bevacizumab, and these patients were treated with durvalumab plus bevacizumab [160, 161].